Compare ETD & AQST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ETD | AQST |
|---|---|---|
| Founded | 1932 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 569.7M | 529.4M |
| IPO Year | 1996 | 2007 |
| Metric | ETD | AQST |
|---|---|---|
| Price | $23.55 | $4.68 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $27.00 | $9.00 |
| AVG Volume (30 Days) | 461.1K | ★ 3.6M |
| Earning Date | 04-29-2026 | 05-01-2026 |
| Dividend Yield | ★ 8.15% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.10 | N/A |
| Revenue | ★ $766,784,000.00 | $67,430,000.00 |
| Revenue This Year | N/A | $10.08 |
| Revenue Next Year | $2.73 | $49.60 |
| P/E Ratio | $20.85 | ★ N/A |
| Revenue Growth | N/A | ★ 0.77 |
| 52 Week Low | $18.28 | $2.94 |
| 52 Week High | $31.41 | $7.55 |
| Indicator | ETD | AQST |
|---|---|---|
| Relative Strength Index (RSI) | 56.07 | 66.99 |
| Support Level | $22.30 | $4.03 |
| Resistance Level | $23.74 | $5.10 |
| Average True Range (ATR) | 0.61 | 0.25 |
| MACD | -0.08 | 0.08 |
| Stochastic Oscillator | 47.55 | 94.98 |
Ethan Allen Interiors Inc through its subsidiaries, operates as an interior design company, and a manufacturer and retailer in the home furnishings marketplace. Its product offerings include fabric chairs, beds, wallpapers, desks, and dining tables among others. The company's reportable segments are; Wholesale and Retail. The Wholesale segment is principally involved in the development of the Ethan Allen brand and encompasses all aspects of design, manufacturing, sourcing, marketing, sale, and distribution of home furnishings and accents. The Retail segment which generates maximum revenue, sells home furnishings and accents to clients through company-operated design centers. Geographically, it derives key revenue from the United States and the rest from other regions.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.